ALT Q3 2021 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$158,000-94.6% YoY

Gross Profit

-$29M-18384.8% margin

Operating Income

-$33M-21015.2% margin

Net Income

-$34M-21208.9% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+15.3%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$237M

Total Liabilities

$28M

Stockholders' Equity

$209M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$158,000	$3M	-94.6%
Gross Profit	-$29M	$3M	-1088.7%
Operating Income	-$33M	-$18M	-81.2%
Net Income	-$34M	-$18M	-88.6%

Revenue Segments

Grant

$100,000100%